Zhejiang Cancer Hospital
🇨🇳China
Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT04190745
- Locations
- 🇨🇳
Jieer Ying, Hangzhou, Zhejiang, China
Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04191343
- Locations
- 🇨🇳
Haijun Zhong, Zhenjiang, Hangzhou, China
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT04189094
Single Cell Sequencing Analysis of Thymoma
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT04162691
- Locations
- 🇨🇳
An Zhao, Hangzhou, China
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
- Conditions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04161352
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 616
- Registration Number
- NCT04135781
- Locations
- 🇨🇳
Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences, Hangzhou, Zhejiang, China
CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT04121975
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT04119674
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Phase 2
Suspended
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04084158
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04066543
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath